Repotrectinib Induces Durable Responses in ROS1+ NSCLC Subsets

Treatment with repotrectinib in patients with ROS1-positive non–small cell lung cancer, specifically those who were tyrosine kinase inhibitor-naïve or -pretreated, continued to demonstrate durable clinical activity, as well as durable intracranial responses.

Related Keywords

Joseph Fiore ,Byoung Chul Cho ,Yonsei University College Of Medicine ,Bristol Myers Squibb ,Lung Cancer Center At Yonsei ,Chul Cho ,Medical Oncology ,Yonsei Cancer Center ,Yonsei University College ,Lung Cancer Center ,Blinded Independent Central Review ,Prescription Drug User Fee Act ,World Conference On Lung Cancer ,Conference ,News ,Iaslc World Conference On Lung Cancer ,Lung Cancer ,Nsclc ,Non Small Cell Lung Cancer ,Repotrectinib ,Nct03093116 ,Trident 1 Trial ,